Form 4: TOI CEO Daniel Virnich Reports Significant Stock Transactions
Insider Transaction Report
The Oncology Institute CEO Daniel Virnich reported the acquisition of 670,608 shares via RSU awards and the sale of 98,534 shares to cover tax liabilities.
Summary
- Daniel Virnich, Chief Executive Officer of The Oncology Institute, Inc. (TOI), reported changes in his beneficial ownership of common stock.
- On March 27, 2026, Virnich acquired 670,608 shares of common stock through RSU awards.
- These RSU awards vest 1/4 on the first anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in three equal annual installments, becoming fully vested on the fourth anniversary, subject to continued service.
- On March 27, 2026, Virnich disposed of 98,534 shares of common stock at a price of $3.07 per share.
- This disposition was executed to cover tax liabilities arising from the vesting of an RSU award on March 31, 2026.
- Following these transactions, Virnich's direct beneficial ownership stands at 2,360,224 shares of common stock.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as slightly positive due to the significant RSU grant to the CEO, aligning his interests with long-term company performance, despite the expected tax-related share sale.
Positives
- The CEO, Daniel Virnich, received a significant grant of 670,608 RSU awards, aligning his long-term interests with shareholder value through future vesting.
Negatives
- The sale of 98,534 shares, even if for tax purposes, represents a reduction in the CEO's direct ownership of the company's common stock.
Future Outlook
The RSU awards have a vesting schedule that extends over four years, indicating a long-term incentive structure for the CEO, subject to continued service with the company.
Industry Context
StockSavvy.ai notes that the grant of Restricted Stock Units (RSUs) is a standard practice in executive compensation across various industries, including healthcare, designed to incentivize long-term performance and align management interests with shareholders. The subsequent sale of shares to cover tax obligations upon vesting is also a common and expected event for RSU recipients.
Related Party Transactions
- The reported transactions involve the Chief Executive Officer, Daniel Virnich, acquiring and disposing of company common stock, which constitutes an insider transaction.
Stakeholder Impact
- Shareholders: The issuance of RSUs can lead to minor dilution over time as shares vest. The CEO's continued significant ownership (2,360,224 shares) maintains alignment with shareholder interests.
- Employees: The RSU grant to the CEO reinforces the company's executive compensation strategy, potentially influencing broader compensation philosophies.
Next Steps
- Future vesting events for the RSU awards will occur annually, with 1/4 vesting on the first anniversary of the Vesting Commencement Date, and the remaining RSUs vesting in three equal annual installments, subject to continued service.
Key Dates
| Date | Description |
|---|---|
| 03/27/2026 | Transaction date for the acquisition of 670,608 common stock via RSU awards and the disposition of 98,534 common stock to cover tax liabilities. |
| 03/31/2026 | Vesting date of an RSU award that resulted in tax liabilities, leading to the share disposition. |
| 04/01/2026 | Signature date of the reporting person's attorney-in-fact. |
Keywords
The Oncology Institute, TOI, Daniel Virnich, CEO, Insider Transaction, Form 4, RSU, Restricted Stock Units, Stock Ownership, Executive Compensation, Share Sale, Tax Liabilities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.